IDEXX Laboratories Inc. Common Stock (IDXX)
Stock · NASDAQ · Health Care
$560.52as of 10/16/2026
Price chart
Active signals
IDXX Signal Track Record
How signals performed across all stocks →What IDXX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | -0.1% | 50% | September 18, 2026 |
| Bollinger Band Breakdown | 22 | +0.4% | 50% | September 8, 2026 |
| Bollinger Band BreakoutActive now | 22 | -0.9% | 45% | August 4, 2026 |
| 200-Day Moving Average TouchActive now | 16 | -3.4% | 31% | March 3, 2026 |
| Any 20-session window (baseline) | -0.5% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IDXX
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematolo…
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Employees
- 11,000
- Website
- www.idexx.com/
Fundamentals
- 1-day range
- $535.29$547.83
- Market cap
- $46.48B
- P/E (trailing)
- 37.51
- P/E (forward)
- 32.72
- EPS (trailing)
- $14.23
- Dividend yield
- —
- Beta
- 1.56
- Avg. volume
- 543.8K
How IDEXX Laboratories Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 20, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
IDEXX Laboratories Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IDXXIDEXX Laboratories Inc. Common Stock$560.36▲ 2.41%Market cap $46.48BP/E 37.51$500.61$769.98
- ORKAOruka Therapeutics Inc. Common Stock$71.93▼ 2.63%Market cap $5.94BP/E —$24.88$115.52
- CLDXCelldex Therapeutics Inc.$27.53▼ 4.84%Market cap $3.26BP/E —$22.1$45.14
- NEOGNeogen Corporation Common Stock$11.81▼ 3.75%Market cap $2.46BP/E —$5.37$14.26
- NTLAIntellia Therapeutics Inc. Common Stock$11.42▲ 0.71%Market cap $1.57BP/E —$7.95$28.25
- NNNNAnbio Biotechnology Class A Ordinary Shares$3.13▼ 5.15%Market cap $1.40BP/E 46.55$3.52$44.73
- QDELQuidelOrtho Corporation Common Stock$12.91▼ 7.19%Market cap $1.11BP/E —$9.92$35.58
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IDXX IDEXX Laboratories Inc. Common Stock | $46.48B | 37.51 | $560.36 | ▲ 2.41% | $500.61$769.98 |
| ORKA Oruka Therapeutics Inc. Common Stock | $5.94B | — | $71.93 | ▼ 2.63% | $24.88$115.52 |
| CLDX Celldex Therapeutics Inc. | $3.26B | — | $27.53 | ▼ 4.84% | $22.1$45.14 |
| NEOG Neogen Corporation Common Stock | $2.46B | — | $11.81 | ▼ 3.75% | $5.37$14.26 |
| NTLA Intellia Therapeutics Inc. Common Stock | $1.57B | — | $11.42 | ▲ 0.71% | $7.95$28.25 |
| NNNN Anbio Biotechnology Class A Ordinary Shares | $1.40B | 46.55 | $3.13 | ▼ 5.15% | $3.52$44.73 |
| QDEL QuidelOrtho Corporation Common Stock | $1.11B | — | $12.91 | ▼ 7.19% | $9.92$35.58 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- JP Morgan Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $750benzinga · 10/16/2026
- Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day AverageBenzinga · 10/5/2026
- IDEXX Laboratories to Release 2026 Third Quarter Financial ResultsYahoo · 10/1/2026
- Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX LaboratoriesYahoo · 9/30/2026
- Companion Animal Diagnostic Market Forecasts Growth from $3.56B (2026) to $5.40B by 2031, Profiling IDEXX Laboratories & ZoetisYahoo · 9/24/2026
- Should You Continue to Hold IDXX Stock in Your Portfolio?Yahoo · 9/23/2026
- IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth TargetsYahoo · 9/20/2026
- IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley ConferenceYahoo · 9/20/2026
- IDEXX (IDXX) Bets an AI Scribe Can Sell More Pet DiagnosticsYahoo · 9/19/2026
Insider Activity
Insider Actions →- Lawrence D. Kingsley · September 4, 2026 · Option Exercise2.2K @ $114.17
- Lawrence D. Kingsley · September 4, 2026 · Sale2.2K @ $532.08
- Andrew Emerson · August 20, 2026 · Option Exercise265 @ $178.26
- Andrew Emerson · August 20, 2026 · Tax Withholding86
- Joseph L. Hooley · July 30, 2026 · Grant49 @ $558.8
- George Fennell · June 1, 2026 · Option Exercise639
- George Fennell · June 1, 2026 · Tax Withholding284 @ $566.79
- Karen Peacock · May 12, 2026 · Grant234
- Karen Peacock · May 12, 2026 · Grant525
- Sam Samad · May 12, 2026 · Grant234
- Sam Samad · May 12, 2026 · Grant525
- Lawrence D. Kingsley · May 12, 2026 · Grant234
- Lawrence D. Kingsley · May 12, 2026 · Grant168
- Irene Chang Britt · May 12, 2026 · Grant234
- Irene Chang Britt · May 12, 2026 · Grant525
Institutional Ownership
March 31, 2026
- Total shares held
- 65.59M
- Total value held
- $35.61B
- Institutional holders
- 1285
- Unknown8.37M
- Unknown5.18M
- Unknown3.67M
- Unknown2.66M
- Unknown1.68M
- Unknown1.63M
- Unknown1.50M
- Unknown1.47M
- Unknown1.32M
- Unknown946.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
KeyBanc initiates IDEXX coverage with Sector Weight rating
KeyBanc has started covering IDEXX Laboratories, assigning it a Sector Weight rating. This move adds to analyst attention as investors look ahead to the company's upcoming Q3 2026 earnings report. The stock is currently trading near its 52-week high, reflecting strong recent performance.
KeyBanc initiates IDEXX coverage with Sector Weight rating. KeyBanc has started covering IDEXX Laboratories, assigning it a Sector Weight rating. This move adds to analyst attention as investors look ahead to the company's upcoming Q3 2026 earnings report. The stock is currently trading near its 52-week high, reflecting strong recent performance.